Countering hepatitis B virus infection using RNAi: How far are we from the clinic?

Reviews in Medical Virology

Volumn 21, Issue 6, 2011, Pages 383-396

  Ivacik, Dejana ^a   Ely, Abdullah ^a   Arbuthnot, Patrick ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

DICER; LIPOPLEX; RNA INDUCED SILENCING COMPLEX; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; VIRUS VECTOR;

DNA TEMPLATE; DRUG MECHANISM; DRUG TARGETING; GENE SILENCING; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERSISTENT VIRUS INFECTION; REVIEW; RNA INTERFERENCE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AGENTS; CARCINOMA, HEPATOCELLULAR; GENE SILENCING; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; RNA, SMALL INTERFERING; VIRUS REPLICATION;

EID: 80055083415     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.705     Document Type: Review

References (143)

1. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.
2. Arbuthnot P. Harnessing RNA interference for the treatment of viral infections. Drug News & Perspectives 2010; 23: 341-350.
3. Arbuthnot P, Carmona S, Ely A. Exploiting the RNA interference pathway to counter hepatitis B virus replication. Liver International 2005; 25: 9-15.
4. Arbuthnot P, Longshaw V, Naidoo T, Weinberg MS. Opportunities for treating chronic hepatitis B and C virus infection using RNA interference. Journal of Viral Hepatitis 2007; 14: 447-459.
5. Arbuthnot P, Thompson LJ. Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma. World Journal of Gastroenterology 2008; 14: 1670-1681.
6. Chen Y, Cheng G, Mahato RI. RNAi for treating hepatitis B viral infection. Pharmaceutical Research 2008; 25: 72-86.
7. McCaffrey AP. RNA interference inhibitors of hepatitis B virus. Annals of the New York Academy of Sciences 2009; 1175: 15-23.
8. Weinberg MS, Arbuthnot P. Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection. Genome Med 2010; 2: 28.
9. Beck J, Nassal M. Hepatitis B virus replication. World Journal of Gastroenterology 2007; 13: 48-64.
10. Seeger C, Mason WS. Hepatitis B virus biology. Microbiology and Molecular Biology Reviews 2000; 64: 51-68.
11. Kew MC. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2011; 26 Suppl 1: 144-152.
12. Hepatitis B virus Fact sheet No. 204 (Revised 2008).
13. Arbuthnot P, Kew M. Hepatitis B virus and hepatocellular carcinoma. International Journal of Experimental Pathology 2001; 82: 77-100.
14. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: a Cancer Journal for Clinicians 2005; 55: 74-108.
15. Chien YC, Jan CF, Kuo HS, Chen CJ. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20years after it was launched. Epidemiologic Reviews 2006; 28: 126-135.
16. Lee CL, Ko YC. Hepatitis B vaccination and hepatocellular carcinoma in Taiwan. Pediatrics 1997; 99: 351-353.
17. Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y. Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clinical Gastroenterology and Hepatology 2008; 6: 268-274.
18. Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver International 2011; 31 Suppl 1: 111-116.
19. Cummings IW, Browne JK, Salser WA, et al. Isolation, characterization, and comparison of recombinant DNAs derived from genomes of human hepatitis B virus and woodchuck hepatitis virus. Proceedings of the National Academy of Sciences of the United States of America 1980; 77: 1842-1846.
20. Summers J, O'Connell A, Millman I. Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles. Proceedings of the National Academy of Sciences of the United States of America 1975; 72: 4597-4601.
21. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986; 47: 451-460.
22. Moolla N, Kew M, Arbuthnot P. Regulatory elements of hepatitis B virus transcription. Journal of Viral Hepatitis 2002; 9: 323-331.
23. Seeger C, Ganem D, Varmus HE. Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science 1986; 232: 477-484.
24. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nature Reviews. Molecular Cell Biology 2005; 6: 376-385.
25. Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nature Reviews. Molecular Cell Biology 2008; 9: 219-230.
26. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003; 425: 415-419.
27. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO Journal 2004; 23: 4051-4060.
28. Yi R, Qin Y, Macara IG, Cullen, BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes & Development 2003; 17: 3011-3016.
29. Zhang H, Kolb FA, Jaskiewicz L, Westhof E, Filipowicz W. Single processing center models for human Dicer and bacterial RNase III. Cell 2004; 118: 57-68.
30. Chendrimada TP, Gregory RI, Kumaraswamy E, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005; 436: 740-744.
31. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003; 115: 209-216.
32. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
33. Zeng Y, Yi R, Cullen BR. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proceedings of the National Academy of Sciences of the United States of America 2003; 100: 9779-9784.
34. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Molecular Cell 2004; 15: 185-197.
35. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009; 457: 426-433.
36. Manjunath N, Dykxhoorn DM. Advances in synthetic siRNA delivery. Discovery Medicine 2010; 9: 418-430.
37. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
38. Paul CP, Good PD, Winer I, Engelke DR. Effective expression of small interfering RNA in human cells. Nature Biotechnology 2002; 20: 505-508.
39. Carmona S, Ely A, Crowther C, et al. Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs. Molecular Therapy 2006; 13: 411-421.
40. McCaffrey AP, Nakai H, Pandey K, et al. Inhibition of hepatitis B virus in mice by RNA interference. Nature Biotechnology 2003; 21: 639-644.
41. Shlomai A, Shaul Y. Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology 2003; 37: 764-770.
42. Uprichard SL, Boyd B, Althage A, Chisari FV. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 773-778.
43. Sun D, Rosler C, Kidd-Ljunggren K, Nassal M. Quantitative assessment of the antiviral potencies of 21 shRNA vectors targeting conserved, including structured, hepatitis B virus sites. Journal of Hepatology 2010; 52: 817-826.
44. Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O, Galun E. Small interfering RNA inhibits hepatitis B virus replication in mice. Molecular Therapy 2003; 8: 769-776.
45. Hamasaki K, Nakao K, Matsumoto K, Ichikawa T, Ishikawa H, Eguchi K. Short interfering RNA-directed inhibition of hepatitis B virus replication. FEBS Letters 2003; 543: 51-54.
46. Klein C, Bock CT, Wedemeyer H, et al. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology 2003; 125: 9-18.
47. DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 8800-8805.
48. Li L, Lin X, Khvorova A, Fesik SW, Shen Y. Defining the optimal parameters for hairpin-based knockdown constructs. RNA 2007; 13: 1765-1774.
49. Schopman NC, Liu YP, Konstantinova P, ter Brake O, Berkhout B. Optimization of shRNA inhibitors by variation of the terminal loop sequence. Antiviral Research 2010; 86: 204-211.
50. Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals off-target gene regulation by RNAi. Nature Biotechnology 2003; 21: 635-637.
51. Klinghoffer RA, Magnus J, Schelter J, Mehaffey M, Coleman C, Cleary MA. Reduced seed region-based off-target activity with lentivirus-mediated RNAi. RNA 2010; 16: 879-884.
52. Ui-Tei K, Naito Y, Zenno S, et al. Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Research 2008; 36: 2136-2151.
53. Jackson AL, Burchard J, Leake D, et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 2006; 12: 1197-1205.
54. Bramsen JB, Pakula MM, Hansen TB, et al. A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Research 2010; 38: 5761-5773.
55. Chen PY, Weinmann L, Gaidatzis D, et al. Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 2008; 14: 263-274.
56. Hean J, Crowther C, Ely A, et al. Inhibition of hepatitis B virus replication in vivo using lipoplexes containing altritol-modified antiviral siRNAs. 2010.
57. Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotechnology 2005; 23: 1002-1007.
58. Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nature Medicine 2005; 11: 263-270.
59. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nature Biotechnology 2005; 23: 457-462.
60. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008; 452: 591-597.
61. Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Molecular Therapy 2006; 13: 494-505.
62. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537-541.
63. Scherer LJ, Frank R, Rossi JJ. Optimization and characterization of tRNA-shRNA expression constructs. Nucleic Acids Research 2007; 35: 2620-2628.
64. Dyer V, Ely A, Bloom K, Weinberg M, Arbuthnot P. tRNA Lys3 promoter cassettes that efficiently express RNAi-activating antihepatitis B virus short hairpin RNAs. Biochemical and Biophysical Research Communications 2010; 398: 640-646.
65. Ely A, Naidoo T, Arbuthnot P. Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles. Nucleic Acids Research 2009; 37: e91.
66. Ely A, Naidoo T, Mufamadi S, Crowther C, Arbuthnot P. Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo. Molecular Therapy 2008; 16: 1105-1112.
67. Liu YP, Haasnoot J, ter Brake O, Berkhout B, Konstantinova P. Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Research 2008; 36: 2811-2824.
68. Snyder LL, Esser JM, Pachuk CJ, Steel LF. Vector design for liver-specific expression of multiple interfering RNAs that target hepatitis B virus transcripts. Antiviral Research 2008; 80: 36-44.
69. Robbins MA, Li M, Leung I, et al. Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nature Biotechnology 2006; 24: 566-571.
70. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nature Genetics 2003; 34: 263-264.
71. Fish RJ, Kruithof EK. Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors. BMC Molecular Biology 2004; 5: 9.
72. Hemmi H, Takeuchi O, Kawai T, et al. A toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-745.
73. Sells MA, Chen ML, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proceedings of the National Academy of Sciences of the United States of America 1987; 84: 1005-1009.
74. Sells MA, Zelent AZ, Shvartsman M, and Acs G. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. Journal of Virology 1988; 62: 2836-2844.
75. Gripon P, Rumin S, Urban S, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proceedings of the National Academy of Sciences of the United States of America 2002; 99: 15655-15660.
76. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chemico-Biological Interactions 2007; 168: 66-73.
77. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Therapy 1999; 6: 1258-1266.
78. Yang PL, Althage A, Chung J, and Chisari FV. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proceedings of the National Academy of Sciences of the United States of America 2002; 99: 13825-13830.
79. Crowther C, Ely A, Hornby J, et al. Efficient inhibition of hepatitis B virus replication in vivo, using polyethylene glycol-modified adenovirus vectors. Human Gene Therapy 2008; 19: 1325-1331.
80. Guidotti LG, Matzke B, Schaller H, Chisari FV. High-level hepatitis B virus replication in transgenic mice. Journal of Virology 1995; 69: 6158-6169.
81. Marion P, Salazar F, Liittschwager K, et al. A transgenic mouse lineage useful for testing antivirals targeting hepatitis B virus. Frontiers in Viral Hepatitis 2003; 197-202.
82. Raney AK, Eggers CM, Kline EF, et al. Nuclear covalently closed circular viral genomic DNA in the liver of hepatocyte nuclear factor 1 alpha-null hepatitis B virus transgenic mice. Journal of Virology 2001; 75: 2900-2911.
83. Meuleman P, Libbrecht L, De Vos R, et al. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 2005; 41: 847-856.
84. Heckel JL, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 1990; 62: 447-456.
85. Meuleman P, Leroux-Roels G. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. Antiviral Research 2008; 80: 231-238.
86. Mason WS, Seal G, Summers J. Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus. Journal of Virology 1980; 36: 829-836.
87. Tennant BC, Gerin JL. The woodchuck model of hepatitis B virus infection. ILAR Journal 2001; 42: 89-102.
88. Summers J, Smolec JM, Snyder R. A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proceedings of the National Academy of Sciences of the United States of America 1978; 75: 4533-4537.
89. Barker LF, Chisari FV, McGrath PP, et al. Transmission of type B viral hepatitis to chimpanzees. Journal of Infectious Diseases 1973; 127: 648-662.
90. Bertoni R, Sette A, Sidney J, et al. Human class I supertypes and CTL repertoires extend to chimpanzees. Journal of Immunology 1998; 161: 4447-4455.
91. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825-829.
92. Arbuthnot P, Ely A and Weinberg MS. Hepatic delivery of RNA interference activators for therapeutic application. Current Gene Therapy 2009; 9: 91-103.
93. Waddington SN, McVey JH, Bhella D, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132: 397-409.
94. Mowa MB, Crowther C, Arbuthnot P. Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators. Expert Opinion on Drug Delivery 2010; 7: 1373-1385.
95. Toietta G, Mane VP, Norona WS, et al. Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 3930-3935.
96. Croyle MA, Le HT, Linse KD, et al. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Therapy 2005; 12: 579-587.
97. McCaffrey AP, Fawcett P, Nakai H, et al. The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Molecular Therapy 2008; 16: 931-941.
98. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. Journal of Virology 1996; 70: 3227-3234.
99. Sipo I, Fechner H, Pinkert S, et al. Differential internalization and nuclear uncoating of self-complementary adeno-associated virus pseudotype vectors as determinants of cardiac cell transduction. Gene Therapy 2007; 14: 1319-1329.
100. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Therapy 2001; 8: 1248-1254.
101. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Molecular Therapy 2006; 14: 316-327.
102. Grimm D, Kay MA. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Current Gene Therapy 2003; 3: 281-304.
103. Chen CC, Ko TM, Ma HI, et al. Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA. Gene Therapy 2007; 14: 11-19.
104. Chen CC, Sun CP, Ma HI, et al. Comparative study of anti-hepatitis B virus RNA interference by double-stranded adeno-associated virus serotypes 7, 8, and 9. Molecular Therapy 2009; 17: 352-359.
105. Mehendale S, van Lunzen J, Clumeck N, et al. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. AIDS Research and Human Retroviruses 2008; 24: 873-880.
106. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nature Medicine 2006; 12: 342-347.
107. Breckpot K, Emeagi PU, Thielemans K. Lentiviral vectors for anti-tumor immunotherapy. Current Gene Therapy 2008; 8: 438-448.
108. Ciuffi A. Mechanisms governing lentivirus integration site selection. Current Gene Therapy 2008; 8: 419-429.
109. Frecha C, Szecsi J, Cosset FL, Verhoeyen E. Strategies for targeting lentiviral vectors. Current Gene Therapy 2008; 8: 449-460.
110. Lundberg C, Bjorklund T, Carlsson T, et al. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Current Gene Therapy 2008; 8: 461-473.
111. Sarkis C, Philippe S, Mallet J, Serguera C. Non-integrating lentiviral vectors. Current Gene Therapy 2008; 8: 430-437.
112. Schambach A, Baum C. Clinical application of lentiviral vectors - concepts and practice. Current Gene Therapy 2008; 8: 474-482.
113. Valori CF, Ning K, Wyles M, Azzouz M. Development and applications of non-HIV-based lentiviral vectors in neurological disorders. Current Gene Therapy 2008; 8: 406-418.
114. Park F, Ohashi K, Chiu W, Naldini L, Kay MA. Efficient lentiviral transduction of liver requires cell cycling in vivo. Nature Genetics 2000; 24: 49-52.
115. DiGiusto DL, Krishnan A, Li L, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Science Translational Medicine 2010; 2: 36ra-43.
116. DiGiusto DL, Krishnan A, Li L, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Science Translational Medicine 2010; 2: 36ra-43.
117. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proceedings of the National Academy of Sciences of the United States of America 2006; 103: 17372-17377.
118. Nguyen TH, Birraux J, Wildhaber B, et al. Ex vivo lentivirus transduction and immediate transplantation of uncultured hepatocytes for treating hyperbilirubinemic Gunn rat. Transplantation 2006; 82: 794-803.
119. Birraux J, Wildhaber BE, Jond C, Belli DC, Menzel O. Ex vivo hepatocyte gene therapy: increased biosafety protocol for transduction in suspension with lentiviral vectors and immediate transplantation (SLIT). Transplantation 2010; 89: 127-129.
120. Menzel O, Birraux J, Wildhaber BE, et al. Biosafety in ex vivo gene therapy and conditional ablation of lentivirally transduced hepatocytes in nonhuman primates. Molecular Therapy 2009; 17: 1754-1760.
121. Birraux J, Menzel O, Wildhaber B, Jond C, Nguyen TH, Chardot C. A step toward liver gene therapy: efficient correction of the genetic defect of hepatocytes isolated from a patient with Crigler-Najjar syndrome type 1 with lentiviral vectors. Transplantation 2009; 87: 1006-1012.
122. Huang P, He Z, Ji S, et al. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 2011; 475: 386-389.
123. Sekiya S, and Suzuki A. Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature 2011; 475: 390-393.
124. Barteau B, Chevre R, Letrou-Bonneval E, Labas R, Lambert O, Pitard B. Physicochemical parameters of non-viral vectors that govern transfection efficiency. Current Gene Therapy 2008; 8: 313-323.
125. Braun S. Muscular gene transfer using nonviral vectors. Current Gene Therapy 2008; 8: 391-405.
126. Harraghy N, Gaussin A, Mermod N. Sustained transgene expression using MAR elements. Current Gene Therapy 2008; 8: 353-366.
127. Midoux P, Breuzard G, Gomez JP., Pichon C. Polymer-based gene delivery: a current review on the uptake and intracellular trafficking of polyplexes. Current Gene Therapy 2008; 8: 335-352.
128. Montier T, Benvegnu T, Jaffres PA, Yaouanc JJ, Lehn P. Progress in cationic lipid-mediated gene transfection: a series of bio-inspired lipids as an example. Current Gene Therapy 2008; 8: 296-312.
129. Palazzoli F, Carnus E, Wells DJ, Bigot Y. Sustained transgene expression using non-viral enzymatic systems for stable chromosomal integration. Current Gene Therapy 2008; 8: 367-390.
130. Philipp A, Meyer M, Wagner E. Extracellular targeting of synthetic therapeutic nucleic acid formulations. Current Gene Therapy 2008; 8: 324-334.
131. Pitard B. Convergence of opposite sciences for the future development of non viral gene therapy. Current Gene Therapy 2008; 8: 295.
132. Mahon KP, Love KT, Whitehead KA, et al. Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery. Bioconjugate Chemistry 2010; 21: 1448-1454.
133. Ceballos C, Khiati S, Prata CA, et al. Cationic nucleoside lipids derived from universal bases: a rational approach for siRNA transfection. Bioconjugate Chemistry 2010; 21: 1062-1069.
134. Ifediba MA, Medarova Z, Ng SW, Yang J, Moore A. siRNA delivery to CNS cells using a membrane translocation peptide. Bioconjugate Chemistry 2010; 21: 803-806.
135. McCarroll J, Baigude H, Yang CS, Rana TM. Nanotubes functionalized with lipids and natural amino acid dendrimers: a new strategy to create nanomaterials for delivering systemic RNAi. Bioconjugate Chemistry 2010; 21: 56-63.
136. Merkel OM, Mintzer MA, Sitterberg J, Bakowsky U, Simanek EE, Kissel. T. Triazine dendrimers as nonviral gene delivery systems: effects of molecular structure on biological activity. Bioconjugate Chemistry 2009; 20: 1799-1806.
137. Ikeda Y, Kubota D, Nagasaki Y. Simple solid-phase synthesis and biological properties of carbohydrate-oligonucleotide conjugates modified at the 3'-terminus. Bioconjugate Chemistry 2010; 21: 1685-1690.
138. Wu GY, Wu CH. Receptor-mediated gene delivery and expression in vivo. Journal of Biological Chemistry 1988; 263: 14621-14624.
139. Carmona S, Jorgensen MR, Kolli S, et al. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Molecular Pharmaceutics 2009; 6: 706-717.
140. Kim SI, Shin D, Choi TH, et al. Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Molecular Therapy 2007; 15: 1145-1152.
141. Dass CR. Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection. Journal of Molecular Medicine 2004; 82: 579-591.
142. Schmidt C. RNAi momentum fizzles as pharma shifts priorities. Nature Biotechnology 2011; 29: 93-94.
143. Arbuthnot P, Capovilla A, Kew M. Putative role of hepatitis B virus X protein in hepatocarcinogenesis: effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways. Journal of Gastroenterology and Hepatology 2000; 15: 357-368.